دورية أكاديمية
أعرض في EDS

In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug.

التفاصيل البيبلوغرافية
العنوان: In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug.
المؤلفون: Rasul A; Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan., Imran Khan M; Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, Pakistan., Ur Rehman M; Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan., Abbas G; Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan., Aslam N; Department of Biochemistry, Government College University, Faisalabad, Pakistan., Ahmad S; Cancer Center, Faculty of Health Sciences, University of Macau, Taipa, Macau, People's Republic of China., Abbas K; Department of Pharmacognosy, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan., Akhtar Shah P; University College of Pharmacy, University of the Punjab, Lahore, Pakistan., Iqbal M; Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan., Ahmed Al Subari AM; Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan., Shaheer T; Department of Pharmacognosy, Xian Jiaotong University, Xian, People's Republic of China., Shah S; Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
المصدر: International journal of nanomedicine [Int J Nanomedicine] 2020 Oct 14; Vol. 15, pp. 7937-7949. Date of Electronic Publication: 2020 Oct 14 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Auckland : DOVE Medical Press,
مواضيع طبية MeSH: Drug Carriers/*chemistry , Immunosuppressive Agents/*chemistry , Immunosuppressive Agents/*pharmacology , Surface-Active Agents/*chemistry, Animals ; Biological Availability ; Cholesterol/chemistry ; Cyclosporine/administration & dosage ; Cyclosporine/chemistry ; Cyclosporine/pharmacokinetics ; Cyclosporine/pharmacology ; Drug Liberation ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/pharmacokinetics ; Liposomes ; Particle Size ; Rabbits
مستخلص: Background: Cyclosporine A (CsA) is an exceptional immunosuppressant used for the treatment of immune disorders. Niosomal vesicles are promising drug carriers that are formed by self-association of nonionic surfactants and cholesterol in an aqueous phase. The objective of the study was to formulate combined nonionic surfactant based vesicles and to evaluate their in vitro characterization, release studies and in vivo studies.
Materials and Methods: Five niosomal formulations (F 7 to F 11 ) were prepared using the thin film hydration method. The molar ratio of cholesterol and non-ionic surfactant taken was 1:1. In formulation F 10 , the combination of surfactants Span 20 and Brij 35 was used. The niosomes were characterized by zeta sizer and SEM for particle size analysis, in vitro drug release and stability studies. The pharmacokinetic studies were conducted on healthy albino rabbits.
Results: The size of niosome was found in the range of 427.1 nm to 972.3 nm. SEM image of optimized formulations F 10 exhibit the spherical nature of niosomal vesicles. DSC thermograms of niosomal formulations exhibited a broadened endothermic peak. The stability study exhibited that all formulations are stable and negligible change of vesicle size and entrapment was observed with time. The percentage drug release was significantly higher as compared to CsA plain dispersion for all niosomal formulations at pH 1.2 and 7.4. The release kinetic behavior showed that all preparations were best described by zero order and can release active ingredient in a sustained manner. The pharmacokinetic data showed the test formulation (F10) possessed greater bioavailability as compared to the reference formulation (CsA aqueous dispersion).
Conclusion: The formulation F 10 demonstrated a comparatively more delayed rate of release with enhanced dissolution as compared to a single surfactant scheme. The F 10 formulation can be a remarkable nanotechnology for prolonged delivery of CsA orally with improved dissolution profile and bioavailability.
Competing Interests: The authors report no conflicts of interest for this work.
(© 2020 Rasul et al.)
References: J Pharm Bioallied Sci. 2013 Oct;5(4):318-25. (PMID: 24302841)
J Drugs Dermatol. 2012 Aug;11(8):979-87. (PMID: 22859244)
Springerplus. 2016 Aug 15;5(1):1349. (PMID: 27588242)
Int J Nanomedicine. 2013;8:421-30. (PMID: 23378764)
Scientifica (Cairo). 2016;2016:6492953. (PMID: 27293976)
J Pharm Sci. 2000 Apr;89(4):429-42. (PMID: 10737905)
Iran J Pharm Res. 2018;17(Suppl2):1-11. (PMID: 31011337)
Int J Nanomedicine. 2015 Jul 29;10:4797-813. (PMID: 26251598)
Pharmaceutics. 2018 Oct 13;10(4):. (PMID: 30322124)
Int J Pharm Investig. 2015 Jan-Mar;5(1):65-72. (PMID: 25599035)
Eur J Pharm Sci. 2016 Dec 1;95:88-95. (PMID: 27600819)
ScientificWorldJournal. 2014 Feb 02;2014:959741. (PMID: 24672401)
Curr Drug Deliv. 2015;12(2):192-9. (PMID: 25056419)
Drug Des Devel Ther. 2016 Aug 02;10:2421-33. (PMID: 27536063)
Eur J Pharm Sci. 2001 May;13(2):123-33. (PMID: 11297896)
Nanomedicine (Lond). 2010 Feb;5(2):287-306. (PMID: 20148639)
Int J Nanomedicine. 2014 Oct 28;9:4991-9. (PMID: 25378925)
Int J Pharm. 2012 Aug 20;433(1-2):142-8. (PMID: 22595640)
AAPS PharmSciTech. 2015 Feb;16(1):108-17. (PMID: 25204859)
Indian J Pharm Sci. 2010 Mar;72(2):252-5. (PMID: 20838535)
J Adv Pharm Technol Res. 2010 Oct;1(4):374-80. (PMID: 22247876)
AAPS PharmSciTech. 2012 Sep;13(3):826-35. (PMID: 22644706)
Pharm Dev Technol. 2013 May-Jun;18(3):667-72. (PMID: 22468904)
AAPS PharmSciTech. 2010 Sep;11(3):1119-27. (PMID: 20635228)
Drug Dev Ind Pharm. 2011 Dec;37(12):1491-508. (PMID: 21707323)
Pharmazie. 2015 Dec;70(12):784-90. (PMID: 26817275)
AAPS PharmSciTech. 2009;10(4):1186-92. (PMID: 19856107)
Methods Mol Biol. 2012;929:377-89. (PMID: 23007438)
Indian J Pharm Sci. 2014 Mar;76(2):132-7. (PMID: 24843186)
Res Pharm Sci. 2010 Jul;5(2):107-17. (PMID: 21589799)
J Transplant. 2012;2012:230386. (PMID: 22263104)
Expert Opin Drug Deliv. 2013 Feb;10(2):261-72. (PMID: 23252629)
J Am Soc Nephrol. 1998 Sep;9(9):1751-6. (PMID: 9727384)
فهرسة مساهمة: Keywords: cyclosporine A; in vitro study; niosomes; nonionic surfactants
المشرفين على المادة: 0 (Drug Carriers)
0 (Immunosuppressive Agents)
0 (Liposomes)
0 (Surface-Active Agents)
83HN0GTJ6D (Cyclosporine)
97C5T2UQ7J (Cholesterol)
تواريخ الأحداث: Date Created: 20201029 Date Completed: 20201120 Latest Revision: 20220417
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7569247
DOI: 10.2147/IJN.S268846
PMID: 33116510
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-2013
DOI:10.2147/IJN.S268846